Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fulyzaq Review Shows FDA Adapting Smoothly To Adaptive Trial Design

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Review documents show that Fulyzaq’s clear, if modest, treatment effect compared to placebo was buttressed by a series of exploratory subgroup analyses suggesting greater efficacy in sicker patients.

Advertisement

Related Content

Case Studies In FDA's Regulatory Interpretation Of Clinical Trials
Review Of Reviews: Drug Review Profiles 2013
Review Of Reviews: Drug Review Profiles 2013
A Question Of Identity: Drug & Botanical Perspectives On Manufacturing Clash In Fulyzaq Review
A Question Of Identity: Drug & Botanical Perspectives On Manufacturing Clash In Fulyzaq Review
Botanical Review Team Develops “Post-CMC” Approach
Best Practices For Adaptive Trial Designs Continue To Evolve
Sponsors’ Use Of Adaptive Designs Appears To Be Growing
Adaptive Trials Could Have A Steep Regulatory Learning Curve

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel